Rebhan Dissertation ohne Lebenslauf - OPUS - Universität Würzburg

103. Ruschitzka F, Quaschning T, Noll G, deGottardi A, Rossier MF, Enseleit
F, Hurlimann D, Lüscher TF, Shaw SG. Endothelin 1 type a receptor
antagonism prevents vascular dysfunction and hypertension induced by
11beta-hydroxysteroid dehydrogenase inhibition: role of nitric oxide.
Circulation 103: 3129-35, 2001.
104. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of
an endothelin-receptor antagonist, bosentan, on blood pressure in
patients with essential hypertension. Bosentan Hypertension
Investigators. N Engl J Med 338: 784-90, 1998.
105. Le Monnier de Gouville AC, Mondot S, Lippton H, Hyman A, Cavero I.
Hemodynamic and pharmacological evaluation of the vasodilator and
vasoconstrictor effects of endothelin-1 in rats. J Pharmacol Exp Ther
252: 300-11, 1990.
106. Goto K, Yanagisawa M, Kimura S, Masaki T. Cardiovascular effects of
endothelin. Jpn Circ J 56: 162-9, 1992.
107. Sorensen SS, Madsen JK, Pedersen EB. Systemic and renal effect of
intravenous infusion of endothelin-1 in healthy human volunteers. Am J
Physiol 266: F411-F418, 1994.
108. Ohuchi T, Kuwaki T, Ling GY, Dewit D, Ju KH, Onodera M, Cao WH,
Yanagisawa M, Kumada M. Elevation of blood pressure by genetic and
pharmacological disruption of the ETB receptor in mice. Am J Physiol
276: R1071-R1077, 1999.
109. Webb DJ, Monge JC, Rabelink TJ, Yanagisawa M. Endothelin: new
discoveries and rapid progress in the clinic. Trends Pharmacol Sci 19: 5-
8, 1998.
110. Ohuchi T, Yanagisawa M, Gariepy CE. Renal tubular effects of
endothelin-B receptor signaling: its role in cardiovascular homeostasis